Actively Recruiting
Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2023-02-08
125
Participants Needed
1
Research Sites
266 weeks
Total Duration
On this page
Sponsors
S
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead Sponsor
G
Guangzhou Burning Rock Dx Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This project is the first application, which is applied as a single center project and applied according to the screening quantity. This project is a multi-omics approach to explore biomarkers associated with prognosis after secondary radical resection of recurrent and metastatic colorectal cancer. Main research objectives: 1. To detect DNA mutation and methylation in tumor tissues by NGS detection technology (the methylation dimension should be detected in adjacent tissues at the same time), and to explore specific molecular markers related to prognosis; 2. Using NGS test technology of blood in patients with preoperative and postoperative blood ctDNA mutations and methylation double dimension testing, respectively, to explore the preoperative and postoperative ctDNA mutations and the correlation between methylation status and recurrence, including but not limited to predict patients with recurrence of sensitivity, specificity, positive predictive value, negative predictive value and recurrence warning time and other indicators. Main contents: This study intends to include single site for the first time/organ metastasis after radical treatment and surgical indications again in patients with colorectal adenocarcinoma (including but not limited to spread to the liver, lung metastasis, peritoneal metastasis, lymph node metastasis and other organ metastasis), collected in patients with preoperative peripheral blood and tissue samples, tissue adjacent to carcinoma and postoperative peripheral blood, NGS detection technology was used to detect DNA and mutation in the relevant samples, combined with clinical treatment and prognosis information of patients, and then explore biomarkers for predicting recurrence risk.
CONDITIONS
Official Title
Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Colorectal cancer patients with first recurrence and metastasis after previous radical resection
- Single site or organ metastasis suitable for reoperation
- Adenocarcinoma confirmed by histology or cytology
- Age 18 years or older at time of informed consent
- Life expectancy of at least 12 weeks
- ECOG performance status score of 0 to 1
You will not qualify if you...
- Currently participating in another intervention study or receiving other drugs or study devices within 4 weeks before enrollment
- Having other malignant tumors at the same time
- Having serious diseases that might affect follow-up and short-term survival as determined by the investigator
- Cardiac disease classified as NYHA class III or IV
- Presence of definite peripheral nerve disease
- Definite hearing loss
- Any other condition deemed unsuitable for inclusion by the researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
Research Team
L
Lifeng Sun
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here